DOI:
10.1039/D1NJ01458G
(Paper)
New J. Chem., 2021,
45, 9020-9025
Nucleophilic vinylic substitution in bicyclic methyleneaziridines: SNVπ or SNVσ?†
Received
24th March 2021
, Accepted 27th April 2021
First published on 28th April 2021
Abstract
A stereodefined monodeuterated methyleneaziridine is shown to be prepared via coordinated reductive ring-opening of an alkynyl epoxide and diastereoselective tethered allene aziridination. Ring-opening of this aziridine with copper-based organometallics follows a pathway that results in stereoretentive substitution, replacing the exo-C–N bond with a corresponding C–C bond; this stereochemical outcome supports either an overall SNVπ mechanism or a C–N insertion/reductive coupling process.
Introduction
In 2010 both we1 and Blakey2 reported the first examples of intramolecular allene aziridination with sulfamate substrates, with the major products being derived in most cases via 2-amidoallylcation intermediates.3 Our group followed this up with the first report4 of analogous reactions of carbamate substrates 1 (Scheme 1) and, in that work, somewhat unstable bicyclic 1,3-oxazolidin-2-one methyleneaziridines 2 were obtained following Lebel's modification5 of the Du Bois protocol6 for Rh(II)-nitrenoid generation. Soon afterwards, Schomaker's group took on the area and developed it extensively, optimising the conditions for generating the methyleneaziridines, engineering the substrates for synthetic tractability (non-terminal allenes, formation of 1,3-oxazinan-2-ones), and elaborating the products into a variety of hydroxy/amino stereotriads and -tetrads and rearranged heterocycles.7
 |
| Scheme 1 The formation and SNV ring-opening of fused 1,3-oxazolidin-2-one methyleneaziridines. | |
In our original publication we noted that the methyleneaziridines were constrained by the ring-fusion such that only the exocyclic aziridine C–N bond is electronically activated in the ground state through hyperconjugation with the carbamate carbonyl π-system. This suggested the possibility of effecting direct substitution/ring-opening at the sp2-carbon, in contrast to the prevailing reactivity of unconstrained methyleneaziridines in which ring-opening occurs preferentially at the sp3-carbon.8 At the time, the only sp2-C–N bond-cleaving processes involved either transition metal-mediated processes9 or stepwise radical addition/β-scission.10 In the event, treatment of methyleneaziridine 2 (R = i-Pr) with lithium diphenylcuprate, or various Grignard reagents in the presence of CuI, led to moderate to good yields of the products 3 of nucleophilic vinylic substitution (SNV).11 That publication concluded with an intention to clarify the stereochemical details of the SNV reaction; the current paper describes studies to that end.
Results and discussion
A stereochemically defined monodeuterated analogue 4 (Scheme 2) of methyleneaziridine 2 (R = i-Pr) was targeted that would allow the stereochemistry of the SNV process to be probed without presenting any steric or electronic bias compared with the original methyleneaziridine. At the outset of this study, a dissociative mechanism for the substitution reaction was ruled out on the basis of the aprotic, low-temperature conditions for the process and the relative instability of a vinylic cation. An out-of-plane (relative to the cleaving C–N bond) stepwise π-addition/elimination process, proceeding via a short-lived formal carbanion located on the terminal methylene carbon, or an equivalent concerted mechanism, would proceed with retention of configuration (SNVπ pathway, → 5). An in-plane concerted process, akin to an SN2 reaction in aliphatic substrates, would lead to inversion of configuration (SNVσ pathway, → 6). The operation of either of these reaction modes would then be revealed in the relative disposition of the newly-formed C–C bond and the adjacent H/D atoms, as shown.
 |
| Scheme 2 Simplified SNV reaction modes of methyleneaziridine 4 with a generic nucleophile Nu−. | |
In the absence of any literature precedent for the synthesis of a stereodefined terminally monodeuterated buta-2,3-dienol,12 a synthesis of methyleneaziridine 4 was proposed based upon diastereoselective coordinated delivery of hydride13 to deuterated alkynyl epoxide 7 (Scheme 3) and the known stereochemical course of the intramolecular aziridination. Following this proposal, trans-2-ethynyl-3-isopropyloxirane14 was stirred with an excess of D2O under basic conditions15 to yield the deuterated alkyne 7 (94% deuterium incorporation). Alkyne 7 was treated with DIBAL in dichloromethane as a non-coordinating solvent that would support epoxide chelation with the aluminium centre, and allene 8 was isolated apparently as one predominant stereoisomer,16 depicted as that expected, and confirmed retrospectively from the NMR data for methyleneaziridine 4. A slightly modified variant of Lebel's protocol for nitrenoid formation afforded consistent yields (∼25%) of methyleneaziridine 4 from N-tosyloxy carbamate 9; lower yields were obtained from carbamate 10 with a range of Rh(II) catalysts including Rh2(OAc)4, Rh2(esp)2,17 and Rh2(TPA)4.18 The stereochemistry in methyleneaziridine 4 was confirmed by comparisons with the NMR data for non-deuterated methyleneaziridine 2,4 and the NOE correlations shown in Fig. 1. In the 1H NMR spectrum of methyleneaziridine 4, the adjacent methine protons at δ 1.81 and 4.35 show 3JHH = 9.5 Hz, indicating a dominating trans-antiperiplanar disposition that places one of the diastereotopic methyls more regularly in close proximity to the CHN and =CHD protons, as seen in the NOE spectra. A simple dihedral drive calculation supports this view (ESI†).19
 |
| Scheme 3 Reagents and conditions: (i) DIBAL, CH2Cl2, 0 °C, 1 h (53%); (ii) (a) CDI, CH3CN, RT, 24 h then add NH2OH·HCl, RT, 24 h; (b) TsCl, Et3N, Et2O, 0 °C → RT, 18 h (9, 62%); (iii) Cl3CCO·NCO, CH2Cl2, 0 °C, 4 h then K2CO3, MeOH, RT, 4 h (10, 97%); (iv) [from 9] K2CO3, Rh2(OAc)4 (5 mol%), CH3CN, RT, 1.5 h (25%); (v) [from 10] Rh(II) catalyst (5 mol%; see text), PhI(OAc)2, MgO, CH2Cl2, reflux, 48 h (4–17%). | |
 |
| Fig. 1 NMR chemical shifts and diagnostic NOE correlations to support the assigned stereochemistry in methyleneaziridine 4. | |
Two variants of the SNV reaction were carried out, both of which converted methyleneaziridine 4 into products with reasonable overall efficiency (Scheme 4). In the first, addition of lithium dimethylcuprate gave a 77% isolated yield of 4-isopropenyl oxazolidinone 11, in which the methyl group was found (see below) to be cis- to the deuterium atom. In the second, a copper-catalysed Grignard reaction with vinylmagnesium bromide gave 4-(buta-1,3-dien-2-yl) oxazolidine 12 as the major product, again with the new C–C bond formed cis- to the deuterium atom. The azirine 13 was also isolated in this work; its formation may be explained by competing addition at the carbonyl followed by 1,4-vinylation of the so-formed α,β-unsaturated ester.20
 |
| Scheme 4 Reagents and conditions: (i) Me2CuLi (1.0 eq.), THF, −20 °C → RT, 30 min (11, 77%); (ii) vinyl-MgBr (2.0 eq), CuI (5 mol%), THF, −50 °C → 0 °C, 1 h (12, 31%; 13, 23%). | |
A combination of NMR experiments, including NOE (Fig. 2) provided support for the stereochemical assignments in SNV products 11 and 12. Notably, in 11 no NOE correlation was observed between the vinyl methyl protons and
CHD; similarly, in compound 12, there were no significant correlations between the vinyl protons and
CHD.
 |
| Fig. 2 Diagnostic NOE correlations to support the assigned stereochemistry in SNV products 11 (left, in CDCl3) and 12 (right, in acetone-d6). Dashed lines indicate important weak/absent correlations. | |
An invertive SNVσ reaction appears to be stereoelectronically accessible in methyleneaziridines 2 and 4, and the microscopic reverse of such a process is supported in the NaNH2-mediated formation of simple methyleneaziridines from 2-bromoallylic amines.21 Despite this, our results clearly rule out the SNVσ mode of ring-opening, the stereochemical outcome being consistent with a (retentive) SNVπ mode of reaction. Setting aside the extent of the involvement of the metal counterions in this process, at one simplistic mechanistic extreme, as the delivery of the methyl or vinyl ligand to the methylene group initiates and charge begins to build on the terminal carbon, the sp2-C–N bond weakens, with progression along this pathway constituting an overall concerted process (cf.Scheme 2). At the other end of the spectrum, an initial carbocupration reaction from the exposed face of the methylene group would generate a short-lived organocopper intermediate that rapidly fragments following rotation via the lower energy pathway11c to place the C–Cu and C–N bonds antiperiplanar to one another. Alternatively, a cross-coupling mechanism may be considered22 in which formal-Cu(I) insertion into the activated sp2-C–N bond (→14, Scheme 5) and reductive elimination/ligand coupling (→15) would deliver the same stereochemical outcome; further research would be necessary to evaluate the viability and implications of such a mechanistic pathway.
 |
| Scheme 5 Retentive ring-opening via formal C–N insertion then ligand coupling from Cu(III) intermediate 14. | |
Conclusions
To the best of our knowledge, the direct nucleophilic sp2 C–N bond cleavage reactions that we reported in 2010 remain the only examples in methyleneaziridine chemistry. In this work, we have demonstrated that the substitution is stereoretentive, ruling out an SNVσ pathway, but the detailed mechanism of these reactions remains open to speculation and further work is intended to close this particular chapter of methyleneaziridine reactivity.23
Experimental
General information
All solvents for anhydrous reactions were obtained dry from Grubbs solvent dispenser units after being passed through an activated alumina column under argon. THF was additionally distilled from sodium/benzophenone ketyl under argon. Commercially available reagents were used as supplied unless otherwise specified. Triethylamine was distilled from CaH2 and stored over KOH pellets under argon. ‘Petrol’ refers to the fraction of light petroleum ether boiling between 30 and 40 °C; ‘ether’ refers to diethyl ether. All reactions were carried out in oven-dried glassware and under an atmosphere of argon unless otherwise specified. Thin layer chromatography (TLC) was carried out using Merck aluminium backed DC60 F254 0.2 mm precoated plates. Spots were then visualised by the quenching of ultraviolet light fluorescence (λmax 254 nm) and then stained and heated with either anisaldehyde or KMnO4 solutions as appropriate. Retention factors (Rf) are reported along with the solvent system used in parentheses. Flash column chromatography was performed using Merck 60 silica gel (particle size 40–63 μm) and the solvent system used is reported in parentheses. Infrared spectra were recorded using a Bruker Tensor 27 FT-IR fitted with a diamond ATR module. Absorption maxima (νmax) are reported in wavenumbers (cm−1) and are described as strong (s), medium (m), weak (w) or broad (br). Proton (1H) and carbon-13 (13C) spectra were recorded on Bruker AVIII HD 500, AVII 500, or AVIII HD 400 spectrometers. Chemical shifts (δH or δC) are reported in parts per million (p.p.m.) downfield of tetramethylsilane, internally referenced (in MestReNova) to the appropriate solvent peak: CDCl3, 7.26/77.16; acetone-d6, 2.05/29.84. Peak multiplicities are described as singlet (s), doublet (d), triplet (t), quartet (q), septet (sept), octet (oct), multiplet (m), and broad (br) or a combination thereof. Coupling constants (J) are rounded to the nearest 0.5 Hz. Assignments are made on the basis of chemical shifts, integrations, and coupling constants, using COSY, HSQC and nOe experiments where appropriate. High Resolution Mass Spectra (HRMS) were recorded by the staff at the Chemistry Research Laboratory (University of Oxford) using a Waters GC-TOF spectrometer (EI/FI). Melting points were recorded on a Griffin melting point apparatus and are uncorrected.
Trans-2-(deuterioethynyl)-3-isopropyloxirane (7)
Trans-2-ethynyl-3-isopropyloxirane (2.03 g, 18.4 mmol) was added to a stirring solution of K2CO3 (3.76 g, 27.2 mmol) in acetonitrile (42 mL). After 30 min, D2O (20 mL) was added and stirring was continued for 5 h. The product was extracted from the reaction mixture into petrol (5 × 100 mL). The combined extracts were dried (MgSO4) and the solvent was removed in vacuo [CARE: the product is volatile] to afford the title compound as a pale yellow oil (1.50 g, 73%, 94% deuterium incorporation). Rf 0.58 (petrol/ether, 3
:
1); νmax/cm−1 (thin film): 2966m, 2589m, 1980w, 1469m; δH (400 MHz, CDCl3) 0.97 (3H, d, J = 7.0 Hz), 0.99 (3H, d, J = 7.0 Hz), 1.52 (1H, oct, J = 7.0 Hz), 2.29 (0.1H, d, J = 1.5 Hz, residual
CH), 2.89 (1H, dd, J = 7.0, 2.0 Hz), 3.11 (1H, d, J = 2.0 Hz); δC (100 MHz, CDCl3) 18.1, 18.7, 30.4, 43.9, 65.4, 71.5 (t, J = 38.5 Hz), 80.3 (t, J = 7.5 Hz).
(3R*,5R*)-6-Deuterio-2-methylhexa-4,5-dien-3-ol (8)
A solution of epoxyalkyne 7 (1.50 g, 13.5 mmol) in dichloromethane (100 mL) was added dropwise to a stirred solution of DIBAL (33.7 mL, 1.0 M in hexane, 33.7 mmol) in dichloromethane (100 mL) at 0 °C. The reaction mixture was stirred for 1 h then quenched by careful addition of water. A satd. aq. solution of Rochelle's salt (200 mL) was added dropwise and the mixture was stirred overnight to allow the solvent layers to separate completely. The mixture was extracted with dichloromethane (5 × 50 mL), the organic layers were combined and washed with brine (50 mL), then dried (MgSO4) and the solvent removed in vacuo. Purification by flash chromatography (petrol/ether, 8
:
1) afforded the title compound as a pale yellow oil (810 mg, 53%). Rf 0.23 (petrol/ether 3
:
1); νmax/cm−1 (thin film) 3409br, 2957m, 2924s, 2854m, 1953w, 1464w, 1379w, 1261w, 1024w; δH (500 MHz, CDCl3) 0.93 (3H, d, J = 7.0 Hz), 0.95 (3H, d, J = 7.0 Hz), 1.67 (1H, d, J = 4.5 Hz), 1.77 (1H, oct, J = 7.0 Hz), 3.92–3.97 (1H, m), 4.83–4.87 (1H, m), 5.23 (1H, t, J = 6.5 Hz); δC (125 MHz, CDCl3) 17.9, 18.2, 34.4, 74.7, 77.3 (t, J = 25.5 Hz), 93.2, 207.5; HRMS (FI+) m/z: [M+] calcd for C7H11DO, 113.0945; found, 113.0951.
(3R*,5R*)-6-Deuterio-2-methylhexa-4,5-dien-3-yl p-toluenesulfonyloxycarbamate (9)
N,N-Carbonyldiimidazole (1.43 g, 8.82 mmol) was added to a solution of alcohol 8 (500 mg, 4.42 mmol) in acetonitrile (25 mL) and the mixture was stirred at RT until the reaction was complete by TLC (∼24 h). Imidazole (1.20 g, 17.6 mmol) and NH2OH·HCl (1.54 g, 22.2 mmol) were added, and stirring was continued until the reaction was complete by TLC (∼24 h). The mixture was filtered and the solvent was removed in vacuo. The residue was then partitioned between hydrochloric acid (12 mL, 1.0 M) and ether (10 mL), and the aqueous phase was extracted with ether (3 × 50 mL). The combined organic layers were washed with brine (25 mL), then dried (Na2SO4) and the solvent was removed in vacuo. Purification of the crude product by flash chromatography (petrol/ether, 3
:
1 → 1
:
1) afforded (3R*,5R*)-6-deuterio-2-methylhexa-4,5-dien-3-yl hydroxycarbamate as a pale yellow oil [454 mg, 60%; 73% based on recovered 8 (90 mg, 18%)]. Rf 0.26 (petrol/ether, 1
:
1); νmax/cm−1 (thin film) 3301br, 2965m, 1956m, 1717s, 1469m, 1387w, 1261s, 1112m, 1024m, 759m; δH (500 MHz, CDCl3) 0.94 (6H, d, J = 7.0 Hz), 1.93 (1H, oct, J = 7.0 Hz), 4.84 (1H, dd, J = 7.0, 1.5 Hz), 5.03 (1H, td, J = 7.0, 1.5 Hz), 5.14 (1H, t, J = 7.0 Hz), 6.77 (1H, br s), 7.21 (1H, s); δC (125 MHz, CDCl3) 18.1 (two peaks), 32.5, 77.1 (t, J = 30.0 Hz), 79.0, 88.9, 159.1, 209.1; HRMS (ESI+) m/z: [M + Na]+ calcd for C8H12DNNaO3, 195.0850; found, 195.0846. Recrystallised p-TsCl (619 mg, 3.25 mmol) was added to a stirred solution of the hydroxycarbamate (554 mg, 3.22 mmol) in dry ether (30 mL) at 0 °C. Triethylamine (0.45 mL, 3.23 mmol) was then added dropwise and stirring was continued for 18 h. The mixture was then diluted with ether (30 mL), washed with brine (2 × 20 mL), dried (Na2SO4), and the solvent removed in vacuo. The crude product was purified by flash chromatography (petrol/ether, 5
:
1 → pure ether) to afford the title compound as a pale yellow oil (893 mg, 85%). Rf 0.50 (petrol/ether, 1
:
1); νmax/cm−1 (thin film) 3284br, 2967m, 1770s, 1737s, 1598m, 1467m, 1379s, 1192s, 1179s, 1019m, 742m; δH (400 MHz, CDCl3) 0.82 (3H, d, J = 7.0 Hz), 0.84 (3H, d, J = 7.0 Hz), 1.80 (1H, oct, J = 7.0 Hz), 2.46 (3H, s), 4.77 (1H, d, J = 6.0 Hz), 4.85–4.95 (2H, m), 7.35 (2H, d, J = 8.0 Hz), 7.76 (1H, s), 7.88 (2H, d, J = 8.0 Hz); δC (100 MHz, CDCl3) 17.8, 18.0, 21.9, 32.4, ∼76.6 (from HSQC; obscured by solvent peak in 1D spectrum), 80.3, 88.2, 129.8, 129.9, 130.5, 146.2, 155.0, 209.1; HRMS (ESI+) m/z: [M + Na]+ calcd for C15H18DNNaO5S, 349.0939; found, 349.0932.
(4R*,5S*,Z)-4-Isopropyl-6-(methylene-d)-3-oxa-1-azabicyclo[3.1.0]hexane-2-one (4)
Rh2(OAc)4 (6.8 mg, 15.4 μmol) and K2CO3 (127 mg, 0.919 mmol) were added to a stirred solution of carbamate 9 (100 mg, 0.306 mmol) in dry acetonitrile (3 mL) at 25 °C. The reaction mixture was stirred vigorously for 90 min then diluted with acetonitrile, filtered, and concentrated in vacuo at RT to give the crude product. Purification by flash chromatography (petrol/ether, 7
:
1) afforded the title compound as a pale yellow oil (12 mg, 25%). Rf 0.49 (petrol/ether 1
:
1); νmax/cm−1 (thin film) 2966w, 1793s, 1761w, 1176m, 1116w, 1072m, 1031s; δH (500 MHz, CDCl3) 1.02 (3H, d, J = 7.0 Hz), 1.08 (3H, d, J = 7.0 Hz), 1.81 (1H, dsept, J = 9.5, 7.0 Hz), 3.62 (1H, d, J = 5.5 Hz), 4.35 (1H, dd, J 9.5, 5.5 Hz), 5.16 (1H, s); δC (100 MHz, CDCl3) 17.6, 19.8, 32.2, 43.7, 83.8, 91.3 (t, J = 25.5 Hz), 130.3, 162.9; HRMS (FI+) m/z: [M+] calcd for C8H10DNO2, 154.0847; found, 154.0847.
(4S*,5R*)-5-Isopropyl-4-[(E)-propen-2-yl-1-d]oxazolidin-2-one (11)
Methyllithium (0.16 mL, 1.6 M solution in ether, 0.256 mmol) was added dropwise to a stirred suspension of CuI (25 mg, 0.131 mmol) in THF (1 mL) in a pear-shaped flask at −20 °C. After 15 min, a solution of methyleneaziridine 4 (20 mg, 0.130 mmol) in THF (1 mL) was added. The mixture was stirred for 30 min, quenched with satd. aq. NH4Cl solution (3 mL), and then allowed to warm to RT. The organic components were extracted into ether (3 × 20 mL), then the combined organic extracts were washed with brine (5 mL), dried (Na2SO4) and concentrated in vacuo. The residue was purified by recrystallisation from ether to afford the title compound (17 mg, 77%) as an off-white solid. Rf 0.20 (ether); m.p. 105–106 °C; νmax/cm−1 (thin film) 3244br, 2985m, 1745s, 1722s, 1468w, 1386s, 1375s, 1220m, 1075m, 993m, 860m; δH (500 MHz, CDCl3) 0.90 and 1.08 (2 × 3H, 2 × d, J = 6.5 Hz), 1.81 (3H, s), 1.87 (1H, oct, J = 6.5 Hz), 4.18–4.24 (2H, m), 4.98 (1H, s), 5.15 (1H, br s); δC (125 MHz, CDCl3) 18.5, 19.1, 19.6, 28.2, 61.7, 86.1, 117.1 (t, J = 24.0 Hz), 141.1, 159.7; HRMS (ESI+) m/z: [M + Na]+ calcd for C9H14DNNaO2, 193.1058; found, 193.1049.
(4S*,5R*)-4-[(E)-buta-1,3-dien-2-yl-1-d]-5-isopropyloxazolidin-2-one (12) and (R*)-2-methyl-1-[(S*)-3-(methyl-d)-2H-azirin-2-yl]propyl pent-4-enoate (13)
Vinylmagnesium bromide (0.25 mL, 1.0 M solution in THF, 0.25 mmol) was added dropwise to a stirred suspension of CuI (1.2 mg, 6.30 μmol) in THF (1 mL) in a pear-shaped flask at −50 °C. After 10 min, a solution of methyleneaziridine 4 (19 mg, 0.123 mmol) in THF (1 mL) was added via canula. The mixture was allowed to warm to –20 °C over 1 h and was then quenched with sat. aq. NH4Cl solution (1 mL). The mixture was stirred for 30 min, warmed to RT, and the organic components were extracted into ether (3 × 20 mL). The combined organic extracts were washed with brine (15 mL), dried (Na2SO4), and concentrated in vacuo. The residue was purified by flash chromatography (petrol/ether, 7
:
1 → 1
:
1) to afford diene 12 (7.0 mg, 31%) as a colourless oil. Rf 0.12 (petrol/ether, 1
:
1); νmax/cm−1 (thin film) 3276br, 2364m, 1753s, 1389m, 1235m, 1023m; δH (400 MHz, CDCl3) 0.90 (3H, d, J = 6.5 Hz), 1.01 (3H, d, J = 6.5 Hz), 1.90 (1H, apparent oct, J = 6.5 Hz), 4.44 (1H, dd, J = 8.0, 7.0 Hz), 4.64 (1H, d, J = 8.0 Hz), 4.97 (1H, br s), 5.19 (1H, d, J = 11.0 Hz), 5.27 (1H, s), 5.31 (1H, d, J = 17.5 Hz), 6.37 (1H, dd, J = 17.5, 11.0 Hz); δH (500 MHz, acetone-d6) 0.89 (3H, d, J 6.5 Hz), 0.95 (3H, d, J = 6.5 Hz), 1.85 (1H, oct, J = 6.5 Hz), 4.48 (1H, dd, J 8.0, 6.5 Hz), 4.78 (1H, d, J = 8.0 Hz), 5.17 (1H, d, J = 11.0 Hz), 5.32 (1H, s), 5.44 (1H, d, J = 17.5 Hz), 6.44 (1H, dd, J = 17.5, 11.0 Hz), 6.68 (1H, br s); δC (125 MHz, acetone-d6) 18.0, 20.3, 29.3 (from HSQC; partially obscured by solvent peak), 57.6, 84.2, 115.5, 117.6 (t, J = 24.5 Hz), 137.5, 143.8, 159.5; HRMS (ESI+) m/z: [M + Na]+ calcd for C10H14DNNaO2, 205.1058; found, 205.1052. Also obtained was azirene 13, a colourless oil (6.0 mg, 23%). Rf 0.74 (petrol/ether, 1
:
1), νmax/cm−1 (thin film) 3080w, 2965m, 1772w, 1730s, 1469m, 1418w, 1370m, 1251m, 1175m, 1106m, 1002m, 915m; δH (500 MHz, CDCl3) 1.02 (3H, d, J = 7.0 Hz), 1.06 (3H, d, J = 7.0 Hz), 1.81 (1H, d, J = 6.0 Hz), 2.03 (1H, oct, J = 7.0 Hz), 2.34–2.41 (4H, m), 2.41–2.45 (2H, m), 4.14 (1H, apparent t, J = 6.0 Hz), 5.01 (1H, dq, J = 10.5, 1.5 Hz), 5.07 (1H, dq, J = 17.0, 1.5 Hz), 5.78–5.87 (1H, m); δC (125 MHz, CDCl3) 14.2 (t, J = 20.0 Hz), 17.8, 18.7, 29.1, 30.9, 31.3, 33.8, 81.2, 115.7, 136.8, 170.8, 172.6; HRMS (ESI+) m/z: [M + Na]+ calcd for C12H18DNNaO2, 233.1371; found, 233.1361.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
The authors are grateful to The Ministry of Education and Science of Ukraine (VP) and the University of Oxford (PD) for funding.
References
- G. C. Feast, L. W. Page and J. Robertson, Chem. Commun., 2010, 46, 2835–2837 RSC.
- A. H. Stoll and S. B. Blakey, J. Am. Chem. Soc., 2010, 132, 2108–2109 CrossRef CAS PubMed.
- See also: R. Liu, PhD Thesis, Brigham Young University, 2007 Search PubMed.
- J. Robertson, G. C. Feast, L. V. White, V. A. Steadman and T. D. W. Claridge, Org. Biomol. Chem., 2010, 8, 3060–3063 RSC.
- H. Lebel, K. Huard and S. Lectard, J. Am. Chem. Soc., 2005, 127, 14198–14199 CrossRef CAS PubMed.
- C. G. Espino and J. Du Bois, Angew. Chem., Int. Ed., 2001, 40, 598–600 CrossRef CAS PubMed.
- Selected papers:
(a) L. A. Boralsky, D. Marston, R. D. Grigg, J. C. Hershberger and J. M. Schomaker, Org. Lett., 2011, 13, 1924–1927 CrossRef CAS PubMed;
(b) R. D. Grigg, J. M. Schomaker and V. Timokhin, Tetrahedron, 2011, 67, 4318–4326 CrossRef CAS;
(c) C. D. Weatherly, J. W. Rigoli and J. M. Schomaker, Org. Lett., 2012, 14, 1704–1707 CrossRef CAS PubMed;
(d) S. C. Schmid, I. A. Guzei, I. Fernández and J. M. Schomaker, ACS Catal., 2018, 8, 7907–7914 CrossRef CAS PubMed.
- M. Shipman, Synlett, 2006, 3205–3217 CrossRef CAS.
-
(a) H. Alper and N. Hamel, Tetrahedron Lett., 1987, 28, 3237–3240 CrossRef CAS;
(b) B. H. Oh, I. Nakamura and Y. Yamamoto, J. Org. Chem., 2004, 69, 2856–2858 CrossRef CAS PubMed;
(c) A. I. Siriwardana, K. K. A. D. S. Kathriarachchi, I. Nakamura, I. D. Gridnev and Y. Yamamoto, J. Am. Chem. Soc., 2004, 126, 13898–13899 CrossRef CAS PubMed;
(d) K. K. A. D. S. Kathriarachchi, A. I. Siriwardana, I. Nakamura and Y. Yamamoto, Tetrahedron Lett., 2007, 48, 2267–2270 CrossRef CAS.
-
(a) N. Prévost and M. Shipman, Org. Lett., 2001, 3, 2383–2385 CrossRef PubMed;
(b) N. Prévost and M. Shipman, Tetrahedron, 2002, 58, 7165–7175 CrossRef.
- Recent reviews:
(a) C. F. Bernasconi and Z. Rappoport, Acc. Chem. Res., 2009, 42, 993–1003 CrossRef CAS PubMed;
(b) S. Chiba, K. Ando and K. Narasaka, Synlett, 2009, 2549–2564 CAS ; see also: ;
(c) Y. Apeloig and Z. Rappoport, J. Am. Chem. Soc., 1979, 101, 5095–5098 CrossRef CAS;
(d) D. Cohen, R. Bar and S. S. Shaik, J. Am. Chem. Soc., 1986, 108, 231–240 CrossRef CAS;
(e) I. Fernández, F. M. Bickelhaupt and E. Uggerud, J. Org. Chem., 2013, 78, 8574–8584 CrossRef PubMed.
- An example was published subsequent to the completion of this work: C. Jarava-Barrera, A. Parra, L. Amenós, A. Arroyo and M. Tortosa, Chem. – Eur. J., 2017, 23, 17478–17481 CrossRef CAS PubMed.
- For example:
(a) M. Ito, Y. Hirata, K. Tsukida, N. Tanaka, K. Hamada, R. Hino and T. Fujiwara, Chem. Pharm. Bull., 1988, 36, 3328–3340 CrossRef CAS PubMed;
(b) A. Baumeler, W. Brade, A. Haag and C. H. Eugster, Helv. Chim. Acta, 1990, 73, 700–715 CrossRef CAS.
-
(a) J. X. Wang, Y. Li and C. X. Zhang, J. Chin. Chem. Soc., 2003, 50, 1183–1187 CrossRef CAS;
(b) H. Jiang, N. Holub, M. W. Paixão, C. Tiberi, A. Falcicchio and K. A. Jørgensen, Chem. – Eur. J., 2009, 15, 9638–9641 CrossRef CAS PubMed.
- S. P. Bew, G. D. Hiatt-Gipson, J. A. Lovell and C. Poullain, Org. Lett., 2012, 14, 456–459 CrossRef CAS PubMed.
- The NMR data for allene 8 showed no doubling in any of the 1H or 13C resonances; cf. J. A. Marshall and G. S. Bartley, J. Org. Chem., 1994, 59, 7169–7171 CrossRef CAS.
- S.-i. Hashimoto, N. Watanabe and S. Ikegami, Tetrahedron Lett., 1992, 33, 2709–2712 CrossRef CAS.
- C. G. Espino, K. W. Fiori, M. Kim and J. Du Bois, J. Am. Chem. Soc., 2004, 126, 15378–15379 CrossRef CAS PubMed.
- The DFT equilibrium geometry of methyleneaziridine 4 was obtained in Spartan ’18 (B3LYP/6-31+G*), then semi-empirical (PM3) relative energies were calculated for constrained conformations in which the H–C–C–H dihedral angle varied from –180° to +180° over 36 steps.
- Comparison 1H NMR (CDCl3) data are available for azirine 16, below, which is compound 4f in H. Alper and J. E. Prickett, Inorg. Chem., 1977, 16, 67–71 CrossRef CAS
.
- J. J. Shiers, M. Shipman, J. F. Hayes and A. M. Z. Slawin, J. Am. Chem. Soc., 2004, 126, 6868–6869 CrossRef CAS PubMed.
-
(a) C. V. Maffeo, G. Marchese, F. Naso and L. Ronzini, J. Chem. Soc., Perkin Trans. 1, 1979, 92–97 RSC;
(b) A. S. E. Karlström, M. Rönn, A. Thorarensen and J.-E. Bäckvall, J. Org. Chem., 1998, 63, 2517–2522 CrossRef PubMed;
(c) I. P. Beletskaya and A. V. Cheprakov, Coord. Chem. Rev., 2004, 248, 2337–2364 CrossRef CAS;
(d) J. E. Ney and J. P. Wolfe, J. Am. Chem. Soc., 2006, 128, 15415–15422 CrossRef CAS PubMed;
(e) C.-Y. Huang and A. G. Doyle, Chem. Rev., 2014, 114, 8153–8198 CrossRef CAS PubMed.
-
(a) B. Pan, F. Li and Y. Zhao, RSC Adv., 2020, 10, 39304–39322 RSC;
(b) K. A. Tehrani and N. De Kimpe, Curr. Org. Chem., 2009, 13, 854–877 CrossRef CAS.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1nj01458g |
|
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2021 |
Click here to see how this site uses Cookies. View our privacy policy here.